A contribution of biomarker collagen type II neoepitope C2C in urine to the diagnosis and prognosis of knee osteoarthritis
Failid
Kuupäev
2022-07-06
Autorid
Ajakirja pealkiri
Ajakirja ISSN
Köite pealkiri
Kirjastaja
Abstrakt
Osteoartriit (OA) on sagedasim liigeshaigus, tabades ligi poolt miljardit inimest maailmas. Põlv on üks peamisi kahjustuskohti. Haiguse kaasaegse käsitluse järgi arenevad kahjustused molekulaarsetest muutustest kuni kudede (kõhr, luu, sünoviaalkest, menisk, sidemed) struktuuri muutusteni. OA on aastate jooksul ebaühtlase kiirusega süvenev haigus, mille puhul stabiilsemad perioodid vahelduvad kiiremate muutustega, kulgedes varajases järgus haigustunnusteta. Seetõttu pakuvad kudede ainevahetuse muutusi peegeldavad molekulaarsed markerid varajast hoiatust koekahjustuse tekkest, võimalust hinnata haiguse kulgu ning tulevikus ka ravivastust. Kuna II tüüpi kollageen (Kol2) on kõhre peamine struktuurne komponent, on OA hindamiseks loodud mitmeid Kol2 lammutamist mõõtvaid teste. Käesolevas uurimuses hindasime OA uue biomarkeri, uC2C kasutusvõimalusi põlve OA (pOA) korral. uC2C on Kol2 lõhustumise neoepitoop C2C uriinis. Võrdlesime uC2C väärtusi röntgenleiu, kõhre otsese vaatlusleiu ja patsiendi kliinilise seisundiga, kasutades erinevaid statistilisi mudeleid. Selgus, et uC2C on sobiv kandidaat pOA varajase diagnostilise testi arendamiseks. C2C sisaldus tõuseb juba haiguse varajases järgus ja on seotud haiguse mitme põhiprotsessiga: kõhre lammutamise ja luukasviste tekkega põlveliigese eri osades. uC2C on hea progressioonimarker naistel: uC2C kõrgem algväärtus ennustab naistel väga hästi (>90%) pOA teket või süvenemist järgneva 3 aasta jooksul. uC2C tase on kõrgem suuremate röntgenmuutuste korral, seega uC2C tase on seotud pOA raskusastmega. uC2C väärtused on suurimad kOA lõppjärgus olevatel haigetel, kes jõuavad liigeseasenduseni suhteliselt noorelt (50–70 a vanuses). Pärast põlveliigese asendamist võib C2C eritumine uriiniga väheneda, suureneda või jääda muutumatuks. Seega ei peata liigeseasendus paljudel juhtudel Kol2 lammutamist organismis ja OA on süsteemsem haigus, kui on seni arvatud. uC2C näib olevat naistel võrreldes meestega parem pOA biomarker.
Osteoarthritis (OA) is the most common joint disease, affecting about half a billion people worldwide. The knee is one of the main sites of impairment. According to the new approach to the disease, the alterations develop from the molecular level to structural changes in tissues (cartilage, bone, synovium, meniscus, ligaments). OA is a disease with an alternating course, with no signs of disease at an early stage. Therefore, molecular markers that reflect changes in tissue metabolism provide an early warning of tissue damage, an opportunity to assess the course of the disease, and a response to future treatment. Because type II collagen (Col2) is a major structural component of cartilage, several tests have been developed to measure Col2 degradation. In the current study, we evaluated the potential use of a new OA biomarker, C2C, in knee OA (kOA). uC2C is a Col2 cleavage neoepitope in urine. We compared uC2C values with X-ray findings, direct visual assessment of cartilage, and clinical status using different statistical models. uC2C is a good candidate for the development of an early diagnostic test for kOA. The level of uC2C is increased in the early stages of kOA and is related to several main processes of kOA: the cartilage lesions and the osteophytes in distinct knee compartments. uC2C is a good marker of progression in women–a higher baseline uC2C is an excellent predictor (> 90%) of the initiation or worsening of kOA over the next 3 years. uC2C is higher in higher X-ray grades, so uC2C levels are associated with the severity of kOA. uC2C values are highest in patients with end-stage kOA who reach joint replacement at a relatively young age (50-70 years). After knee replacement, urinary excretion of C2C may decrease, increase, or remain unchanged. Thus, in many cases, joint replacement does not stop the breakdown of Col2 in the body, and OA is a more systemic disease than previously thought. uC2C appears to be a better biomarker of pOA in women than in men.
Osteoarthritis (OA) is the most common joint disease, affecting about half a billion people worldwide. The knee is one of the main sites of impairment. According to the new approach to the disease, the alterations develop from the molecular level to structural changes in tissues (cartilage, bone, synovium, meniscus, ligaments). OA is a disease with an alternating course, with no signs of disease at an early stage. Therefore, molecular markers that reflect changes in tissue metabolism provide an early warning of tissue damage, an opportunity to assess the course of the disease, and a response to future treatment. Because type II collagen (Col2) is a major structural component of cartilage, several tests have been developed to measure Col2 degradation. In the current study, we evaluated the potential use of a new OA biomarker, C2C, in knee OA (kOA). uC2C is a Col2 cleavage neoepitope in urine. We compared uC2C values with X-ray findings, direct visual assessment of cartilage, and clinical status using different statistical models. uC2C is a good candidate for the development of an early diagnostic test for kOA. The level of uC2C is increased in the early stages of kOA and is related to several main processes of kOA: the cartilage lesions and the osteophytes in distinct knee compartments. uC2C is a good marker of progression in women–a higher baseline uC2C is an excellent predictor (> 90%) of the initiation or worsening of kOA over the next 3 years. uC2C is higher in higher X-ray grades, so uC2C levels are associated with the severity of kOA. uC2C values are highest in patients with end-stage kOA who reach joint replacement at a relatively young age (50-70 years). After knee replacement, urinary excretion of C2C may decrease, increase, or remain unchanged. Thus, in many cases, joint replacement does not stop the breakdown of Col2 in the body, and OA is a more systemic disease than previously thought. uC2C appears to be a better biomarker of pOA in women than in men.
Kirjeldus
Väitekirja elektrooniline versioon ei sisalda publikatsioone
Märksõnad
knee osteoarthritis, biomarkers, collagen type 2, diagnostics